BACKGROUND & AIMS: Children who receive cancer therapy experience numerous acute gastrointestinal (GI) toxicities. However, the long-term GI consequences have not been extensively studied. We evaluated the incidence of long-term GI outcomes and identified treatment-related risk factors. METHODS: Upper GI, hepatic, and lower GI adverse outcomes were assessed in cases from participants in the Childhood Cancer Survivor Study, a study of 14,358 survivors of childhood cancer who were diagnosed between 1970 and 1986; data were compared with those from randomly selected siblings. The median age at cancer diagnosis was 6.8 years (range, 0-21.0 years), and the median age at outcome assessment was 23.2 years (5.6-48.9 years) for survivors and 26.6 years (1.8-56.2 years) for siblings. Rates of self-reported late GI complications (occurred 5 or more years after cancer diagnosis) were determined and associated with patient characteristics and cancer treatments, adjusting for age, sex, and race. RESULTS: Compared with siblings, survivors had increased risk of late-onset complications of the upper GI tract (rate ratio [RR], 1.8; 95% confidence interval [CI], 1.6-2.0), liver (RR, 2.1; 95% CI, 1.8-2.5), and lower GI tract (RR, 1.9; 95% CI, 1.7-2.2). The RRs for requiring colostomy/ileostomy, liver biopsy, or developing cirrhosis were 5.6 (95% CI, 2.4-13.1), 24.1 (95% CI, 7.5-77.8), and 8.9 (95% CI, 2.0-40.0), respectively. Older age at diagnosis, intensified therapy, abdominal radiation, and abdominal surgery increased the risk of certain GI complications. CONCLUSIONS: Individuals who received therapy for cancer during childhood have an increased risk of developing GI complications later in life.
BACKGROUND & AIMS:Children who receive cancer therapy experience numerous acute gastrointestinal (GI) toxicities. However, the long-term GI consequences have not been extensively studied. We evaluated the incidence of long-term GI outcomes and identified treatment-related risk factors. METHODS: Upper GI, hepatic, and lower GI adverse outcomes were assessed in cases from participants in the Childhood Cancer Survivor Study, a study of 14,358 survivors of childhood cancer who were diagnosed between 1970 and 1986; data were compared with those from randomly selected siblings. The median age at cancer diagnosis was 6.8 years (range, 0-21.0 years), and the median age at outcome assessment was 23.2 years (5.6-48.9 years) for survivors and 26.6 years (1.8-56.2 years) for siblings. Rates of self-reported late GI complications (occurred 5 or more years after cancer diagnosis) were determined and associated with patient characteristics and cancer treatments, adjusting for age, sex, and race. RESULTS: Compared with siblings, survivors had increased risk of late-onset complications of the upper GI tract (rate ratio [RR], 1.8; 95% confidence interval [CI], 1.6-2.0), liver (RR, 2.1; 95% CI, 1.8-2.5), and lower GI tract (RR, 1.9; 95% CI, 1.7-2.2). The RRs for requiring colostomy/ileostomy, liver biopsy, or developing cirrhosis were 5.6 (95% CI, 2.4-13.1), 24.1 (95% CI, 7.5-77.8), and 8.9 (95% CI, 2.0-40.0), respectively. Older age at diagnosis, intensified therapy, abdominal radiation, and abdominal surgery increased the risk of certain GI complications. CONCLUSIONS: Individuals who received therapy for cancer during childhood have an increased risk of developing GI complications later in life.
Authors: D K Strickland; C A Riely; C C Patrick; D Jones-Wallace; J M Boyett; B Waters; J F Fleckenstein; P J Dean; R Davila; T E Caver; M M Hudson Journal: Blood Date: 2000-05-15 Impact factor: 22.113
Authors: Meagan Lansdale; Sharon Castellino; Neyssa Marina; Pamela Goodman; Melissa M Hudson; Ann C Mertens; Stephanie M Smith; Wendy Leisenring; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Date: 2010-02-15 Impact factor: 6.860
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Ann C Mertens; Roberta Sposato Walls; Leslie Taylor; Pauline A Mitby; John Whitton; Peter D Inskip; John D Potter; Leslie L Robison Journal: J Clin Epidemiol Date: 2004-09 Impact factor: 7.407
Authors: Bryan V Dieffenbach; Nan Li; Arin L Madenci; Andrew J Murphy; Dana Barnea; Todd M Gibson; Emily S Tonorezos; Wendy M Leisenring; Rebecca M Howell; Lisa R Diller; Qi Liu; Eric J Chow; Gregory T Armstrong; Yutaka Yasui; Kevin C Oeffinger; Christopher B Weldon; Brent R Weil Journal: Eur J Cancer Date: 2020-05-15 Impact factor: 9.162
Authors: Arin L Madenci; Bryan V Dieffenbach; Qi Liu; Daisuke Yoneoka; Jamie Knell; Todd M Gibson; Yutaka Yasui; Wendy M Leisenring; Rebecca M Howell; Lisa R Diller; Kevin R Krull; Gregory T Armstrong; Kevin C Oeffinger; Andrew J Murphy; Brent R Weil; Christopher B Weldon Journal: Cancer Date: 2019-07-19 Impact factor: 6.860
Authors: Anne E Kazak; Matthew C Hocking; Richard F Ittenbach; Anna T Meadows; Wendy Hobbie; Branlyn Werba DeRosa; Ann Leahey; Leslie Kersun; Anne Reilly Journal: Pediatr Blood Cancer Date: 2011-08-19 Impact factor: 3.167
Authors: Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen Journal: Cochrane Database Syst Rev Date: 2019-04-15
Authors: Arin L Madenci; Stacey Fisher; Lisa R Diller; Robert E Goldsby; Wendy M Leisenring; Kevin C Oeffinger; Leslie L Robison; Charles A Sklar; Marilyn Stovall; Rita E Weathers; Gregory T Armstrong; Yutaka Yasui; Christopher B Weldon Journal: J Clin Oncol Date: 2015-08-10 Impact factor: 44.544
Authors: Peter H Asdahl; Kevin C Oeffinger; Vanna Albieri; Melissa Hudson; Wendy M Leisenring; Sarah S Donaldson; Henrik Hasle; Jeanette F Winther; Gregory T Armstrong; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2021-04-12 Impact factor: 3.838
Authors: Mari Wilhelmsson; Heidi Glosli; Marianne Ifversen; Jonas Abrahamsson; Jacek Winiarski; Kirsi Jahnukainen; Henrik Hasle Journal: Bone Marrow Transplant Date: 2018-09-21 Impact factor: 5.483